Corrigendum to "Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study" [Drug Metabol Pharmacokinet 53 (2024) 100532] [0.03%]
“人肠道器官类器官的建立及其在药代动力学研究中的评价”的勘误表 [Drug Metab Pharmacokinet 53 (2024) 100532]
Kentaro Okada,Jumpei Yokota,Tomoki Yamashita et al.
Kentaro Okada et al.
Published Erratum
Drug metabolism and pharmacokinetics. 2024 Dec:59:101042. DOI:10.1016/j.dmpk.2024.101042 2024
Kangle Li,Longjun Gu,Hongwei Cai et al.
Kangle Li et al.
Substance use disorders (SUDs) are complex mental health conditions involving a problematic pattern of substance use. Challenges remain in understanding its neural mechanisms, which are likely to lead to improved SUD treatments. Human brain...
Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial [0.03%]
一项I期临床试验中贾沙替尼在中国肝功能不全受试者中的药代动力学特征研究
Manna Zhao,Hua Zhang,Sheng Ma et al.
Manna Zhao et al.
Jaktinib is a novel Janus kinase (JAK) inhibitor, and a phase I clinical trial of single-dose Jaktinib was conducted in a population of subjects with hepatic impairment to assess the safety, tolerability, and pharmacokinetic characteristics...
Understanding mechanisms of negative food effect for voclosporin using physiologically based pharmacokinetic modeling [0.03%]
基于生理的药代动力学模型理解伏可泊辛药物相互作用的机制
Ayahisa Watanabe,Takanori Akazawa,Motohiro Fujiu
Ayahisa Watanabe
Negative food effect refers to a reduction in bioavailability, when a drug is taken with food. Voclosporin, a highly lipophilic cyclic peptide drug for treatment of active lupus nephritis, has shown negative food effect in clinical trials. ...
Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders [0.03%]
消化系统疾病患者的vonoprazan及CYP3A内源性标志物和遗传变异特征分析
Kenta Sakaguchi,Takafumi Naito,Kohei Hoshikawa et al.
Kenta Sakaguchi et al.
Factors that determine clinical responses to vonoprazan remain unknown. This study aimed to characterize plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders. Fift...
Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations [0.03%]
日本儿科和成人患者服用西罗莫司片剂或颗粒剂的人群药代动力学分析
Taichi Miyazaki,Daichi Hayashi,Akifumi Nozawa et al.
Taichi Miyazaki et al.
A population pharmacokinetic (PopPK) analysis was conducted using data from 215 Japanese administered oral sirolimus (tablet and granule) including healthy subjects and patients with intractable vascular anomalies and other diseases. The an...
Characteristics of membrane transport, metabolism, and target protein binding of cyclic depsipeptide destruxin E in HeLa cells [0.03%]
destructin E的膜转运、代谢及其靶蛋白结合特性研究
Makoto Amifuji,Mai Inagaki,Masahito Yoshida et al.
Makoto Amifuji et al.
Cyclic peptides have attracted attention as new modalities for drug development owing to their unique pharmacokinetic and pharmacodynamic properties. Destruxin E, a 19-membered cyclodepsipeptide, is a promising candidate drug for cancer the...
Kangle Li,Longjun Gu,Hongwei Cai et al.
Kangle Li et al.
Substance use disorders (SUDs) are complex mental health conditions involving a problematic pattern of substance use. Challenges remain in understanding their neural mechanisms, which are likely to lead to improved SUD treatments. Human bra...
Physiologically based pharmacokinetic modeling of CYP2C8 substrate rosiglitazone and its metabolite to predict metabolic drug-drug interaction [0.03%]
基于生理的药代动力学模型预测CYP2C8底物罗格列酮及其代谢产物的代谢药物相互作用
Nilesh Gaud,Dawid Gogola,Anna Kowal-Chwast et al.
Nilesh Gaud et al.
Rosiglitazone is an activator of nuclear peroxisome proliferator-activated (PPAR) receptor gamma used in the treatment of type 2 diabetes mellitus. The elimination of rosiglitazone occurs mainly via metabolism, with major contribution by en...
Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity [0.03%]
尼范努岛和肯尼亚人群疟疾流行地区CYP3A4基因多态性的遗传变异
Kelvin Musyoka,Chim W Chan,Evelyn Marie Gutiérrez Rico et al.
Kelvin Musyoka et al.
Cytochrome P450 3A4 (CYP3A4) enzyme is involved in the metabolism of about 30 % of clinically used drugs, including the antimalarials artemether and lumefantrine. CYP3A4 polymorphisms yield enzymatic variants that contribute to inter-indivi...